Government's reliance on free market economics makes essential drug prices too high for the poor

Mar 27, 2007

Research in Malaysia, published in the latest PLoS Medicine, has established that drugs considered essential for adequate health care are often priced beyond the reach of the poorer members of society. It would cost, for example, three days wages for a low-paid government worker to buy a month’s supply of a commonly prescribed stomach ulcer pill.

The researchers, from Malaysia and from France, looked at the cost of 48 key drugs across the country; 28 were part of a "core list" identified by the World Health Organization as "essential drugs" on the basis of the global burden of disease and 20 reflected health care needs in Malaysia itself. The costs of each medicine were collected from government hospitals, private pharmacies, and dispensing doctors.

The researchers noted both the prices of the "innovator brands’ (made by the original patent holder) and of "generic" brands (an equivalent drug produced by a different company once the exclusive patent has expired). Prices were compared against international reference prices (IRP), which are the average prices offered by not-for-profit drug companies to developing countries. The researchers also compared t he cost of the drugs with daily wages, in order to work out their "affordability."

Prices were on average up to 16 times higher than the IRP. The availability of medicines was also poor, with only 25% of generic medicines available through the public sector. One month’s supply of ranitidine (a drug for stomach ulcers) was equivalent to around three days’ wages for a low-paid government worker, and one month’s supply of fluoxetine (an antidepressant) would cost around 26 days’ wages.

The cost of medicines in Malaysia appears to be much higher than in India and Sri Lanka, where there are government regulations intended to make medicines affordable. In contrast, Malaysia allows market forces to determine drug prices. The researchers say that the Malaysian government should set up mechanisms to prevent drug manufacturers from increasing prices too much and thus ensure greater access to essential medicines. The research has implications for health policy in other parts of the world.

Source: Public Library of Science

Explore further: Rise in anti-psychotic scripts for kids is a serious worry

add to favorites email to friend print save as pdf

Related Stories

Argentina UAVs spot pools and mansions, not empty lots

Sep 26, 2014

Officials in Argentina have used unmanned aerial vehicles (UAVs) to locate undeclared mansions in a crackdown on rich tax evaders. The roots of their suspicions that something was amiss were in properties ...

US Gulf oyster harvest nose-dives since BP spill

Aug 12, 2014

Gulf Coast oyster harvests have declined dramatically in the four years since a BP PLC oil well blew in the U.S.'s worst offshore oil disaster, spilling millions of gallons off Louisiana's coast in 2010.

States debate digital currency

Aug 01, 2014

Now that consumers can use digital currencies like bitcoin to buy rugs from Overstock.com, pay for Peruvian pork sandwiches from a food truck in Washington, D.C., and even make donations to political action committees, states ...

Drugmaker GSK slashes annual profits forecast

Jul 23, 2014

British drugmaker GlaxoSmithKline on Wednesday slashed its 2014 profits forecast as second-quarter earnings sank on the back of weak US trade, adverse currency moves and a Chinese bribery probe.

Recommended for you

Health care M&A leads global deal surge

23 hours ago

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.